Top

Cancer Chemotherapy and Pharmacology

Published in:

01-09-2007 | Original Article

Targeting c-Src kinase enhances tamoxifen’s inhibitory effect on cell growth by modulating expression of cell cycle and survival proteins

Authors: Maricarmen D. Planas-Silva, Kecia N. Hamilton

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/2007

Abstract

Purpose

Many studies have implicated the non-receptor tyrosine kinase c-Src in the development and metastatic progression of many types of cancer. In breast cancer, c-Src has been proposed to mediate the actions of estrogen in cell cycle progression.

Methods

In this study we investigated the interaction between c-Src inhibition and estrogen receptor (ER) function using the ER-positive and tamoxifen-sensitive MCF-7 breast cancer cells.

Results

Pharmacological inhibition of c-Src blocked estrogen-dependent proliferation in MCF-7 cells and enhanced the inhibitory effects of tamoxifen or estrogen-deprivation on cell growth. Maximum inhibition (95%) of cell growth was obtained when tamoxifen and c-Src blockade were combined. Inhibition of c-Src kinase decreased levels of the ER targets c-Myc and cyclin D1 expression but not of Bcl-2. Nevertheless, blocking c-Src kinase in tamoxifen-treated MCF-7 cells led to apoptosis. Inhibition of c-Src kinase altered the ratio of Mcl-1 isoforms in favor of cell death whereas expression of the proapoptotic molecules Bad, Bak, and Bax was not altered. Surprisingly, blocking ER function increased the levels of Bad phosphorylation at serine 112 (BadpS112), an inactive (nonapoptotic) form of Bad. This inactivation of Bad upon ER blockade seemed to depend on c-Src function as chemical inhibition of c-Src kinase reduced BadpS112 levels in cells with impaired ER function but not in estrogen-treated cells.

Conclusion

These results indicate a crucial role for c-Src kinase in the survival of ER-positive breast cancer cells only when ER function is blocked. Therefore, this study suggests that targeting simultaneously c-Src and ER may effectively inhibit growth of ER-positive breast cancer.

Ingle JN (2002) Sequencing of hormonal therapy in breast cancer. Breast J 8:332–337PubMedCrossRef

Ali S, Coombes RC (2002) Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2:101–112PubMedCrossRef

Clarke R, Leonessa F, Welch JN, Skaar TC (2001) Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev 53:25–71PubMed

Hiscox S, Morgan L, Green TP, Barrow D, Gee J, Nicholson RI (2006) Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res Treat 97:263–274PubMedCrossRef

Planas-Silva MD, Bruggeman RD, Grenko RT, Smith JS (2006) Role of c-Src and focal adhesion kinase in progression and metastasis of estrogen receptor-positive breast cancer. Biochem Biophys Res Commun 341:73–81PubMedCrossRef

Riggins RB, Thomas KS, Ta HQ, Wen J, Davis RJ, Schuh NR, Donelan SS, Owen KA, Gibson MA, Shupnik MA, Silva CM, Parsons SJ, Clarke R, Bouton AH (2006) Physical and functional interactions between Cas and c-Src induce tamoxifen resistance of breast cancer cells through pathways involving epidermal growth factor receptor and signal transducer and activator of transcription 5b. Cancer Res 66:7007–7015PubMedCrossRef

Irby RB, Yeatman TJ (2000) Role of Src expression and activation in human cancer. Oncogene 19:5636–5642PubMedCrossRef

Summy JM, Gallick GE (2003) Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 22:337–358PubMedCrossRef

Myoui A, Nishimura R, Williams PJ, Hiraga T, Tamura D, Michigami T, Mundy GR, Yoneda T (2003) C-Src tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. Cancer Res 63:5028–5033PubMed

10.

Ishizawar R, Parsons SJ (2004) c-Src and cooperating partners in human cancer. Cancer Cell 6:209–214PubMedCrossRef

11.

Yeatman TJ (2004) A renaissance for SRC. Nat Rev Cancer 4:470–480PubMedCrossRef

12.

Summy JM, Gallick GE (2006) Treatment for advanced tumors: Src reclaims center stage. Clin Cancer Res 12:1398–1401PubMedCrossRef

13.

Feng W, Webb P, Nguyen P, Liu X, Li J, Karin M, Kushner PJ (2001) Potentiation of estrogen receptor activation function 1 (AF-1) by SRC/JNK through a serine 118- independent pathway. Mol Endocrinol 15:32–45PubMedCrossRef

14.

Shah YM, Rowan BG (2005) The Src kinase pathway promotes tamoxifen agonist action in Ishikawa endometrial cells through phosphorylation-dependent stabilization of estrogen receptor a promoter interaction and elevated steroid receptor coactivator 1 activity. Mol Endocrinol 19:732–748PubMedCrossRef

15.

Castoria G, Migliaccio A, Bilancio A, Di Domenico M, de Falco A, Lombardi M, Fiorentino R, Varricchio L, Barone MV, Auricchio F (2001) PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells. EMBO J 20:6050–6059PubMedCrossRef

16.

Sisci D, Aquila S, Middea E, Gentile M, Maggiolini M, Mastroianni F, Montanaro D, Ando S (2004) Fibronectin and type IV collagen activate ERa AF-1 by c-Src pathway: effect on breast cancer cell motility. Oncogene 23:8920–8930PubMedCrossRef

17.

Song RX-D, Zhang Z, Santen RJ (2005) Estrogen rapid action via protein complex formation involving ERa and Src. Trends Endocrinol Metab 16:347–353PubMedCrossRef

18.

Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107–1112PubMedCrossRef

19.

Planas-Silva MD, Weinberg RA (1997) Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Mol Cell Biol 17:4059–4069PubMed

20.

Migliaccio A, Piccolo D, Castoria G, Di Domenico M, Bilancio A, Lombardi M, Gong W, Beato M, Auricchio F (1998) Activation of the Src/p21^ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J 17:2008–2018PubMedCrossRef

21.

Nam J-S, Ino Y, Sakamoto M, Hirohashi S (2002) Src family kinase inhibitor PP2 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis. Clin Cancer Res 8:2430–2436PubMed

22.

Park HB, Golubovskaya V, Xu L, Yang X, Lee JW, Scully S II, Craven RJ, Cance WG (2004) Activated c-Src increases adhesion, survival and a2-integrin expression in human breast cancer cells. Biochem J 378:559–567PubMedCrossRef

23.

Acconcia F, Barnes CJ, Kumar R (2006) Estrogen and tamoxifen induce cytoskeletal remodeling and migration in endometrial cancer cells. Endocrinology 147:1203–1212PubMedCrossRef

24.

Mandlekar S, Kong A-NT (2000) Mechanisms of tamoxifen-induced apoptosis. Apoptosis 6:469–477CrossRef

25.

Richardson A, Malik RK, Hildebrand JD, Parsons JT (1997) Inhibition of cell spreading by expression of the C-terminal domain of focal adhesion kinase (FAK) is rescued by coexpression of Src or catalytically inactive FAK: a role for paxillin tyrosine phoshorylation. Mol Cell Biol 17:6906–6914PubMed

26.

Butt AJ, McNeil CM, Musgrove EA, Sutherland RL (2005) Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E. Endocr Relat Cancer 12:S47–S59PubMedCrossRef

27.

Lu R, Serrero G (2001) Mediation of estrogen mitogenic effect in human breast cancer MCF-7 cells by PC-cell-derived growth factor (PCDGF/granulin precursor). Proc Natl Acad Sci USA 98:142–147PubMedCrossRef

28.

Wolter KG, Hsu Y-T, Smith CL, Nechushtan A, Xi X-G, Youle RJ (1997) Movement of Bax from the cytosol to mitochondria during apoptosis. J Cell Biol 139:1281–1292PubMedCrossRef

29.

Teixeira C, Reed JC, Pratt MAC (1995) Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 55:3902–3907PubMed

30.

Huang Y, Ray S, Reed JC, Ibrado AM, Tang C, Nawabi A, Bhalla K (1997) Estrogen increases intracellular p26Bcl-2 to p21Bax ratios and inhibits taxol-induced apoptosis of human breast cancer MCF-7 cells. Breast Cancer Res Treat 42:3–81CrossRef

31.

Perillo B, Sasso A, Abbondanza C, Palumbo G (2000) 17ß-estradiol inhibits apoptosis in MCF-7 cells, inducing bcl-2 expression via two estrogen-responsive elements present in the coding sequence. Mol Cell Biol 20:2890–2901PubMedCrossRef

32.

Leek RD, Kaklamanis L, Pezzella F, Gatter KC, Harris AL (1994) bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer 69:135–139PubMed

33.

Diel P, Smolnikar K, Michna H (1999) The pure antiestrogen ICI 182780 is more effective in the induction of apoptosis and down regulation of BCL-2 than tamoxifen in MCF-7 cells. Breast Cancer Res Treat 58:87–97PubMedCrossRef

34.

Yang Q, Sakurai T, Jing X, Utsunomiya H, Shan L, Nakamura Y, Nakamura M, Oura S, Suzuma T, Yoshimura G, Umemura T, Kokawa Y, Kakudo K (1999) Expression of Bcl-2, but not Bax, correlates with estrogen receptor status and tumor proliferation in invasive breast carcinoma. Pathol Int 49:775–780PubMedCrossRef

35.

Niu G, Bowman T, Huang M, Shivers S, Reintgen D, Daud A, Chang A, Kraker A, Jove R, Yu H (2002) Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 21:7001–7010PubMedCrossRef

36.

Craig RW (2002) MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis. Leukemia 16:444–454PubMedCrossRef

37.

Fernando RI, Wimalasena J (2004) Estradiol abrogates apoptosis in breast cancer cells through inactivation of BAD: ras-dependent nongenomic pathways requiring signaling through ERK and Akt. Mol Biol Cell 15:3266–3284PubMedCrossRef

38.

Chen T, George JA, Taylor CC (2006) Src tyrosine kinase as a chemotherapeutic target: is there a clinical case? AntiCancer Drugs 17:123–131PubMedCrossRef

39.

Prathapam T, Tegen S, Oskarsson T, Trumpp A, Martin GS (2006) Activated Src abrogates the Myc requirement for the G_O/G₁ transition but not for the G₁/S transition. Proc Acad Sci USA 103:2695–2700CrossRef

40.

Eischen CM, Packham G, Nip J, Fee BE, Hiebert SW, Zambetti GP, Cleveland JL (2001) Bcl-2 is an apoptotic target suppressed by both c-Myc and E2F-1. Oncogene 20:6983–6993PubMedCrossRef

41.

Pratesi G, Perego P, Zunino F (2001) Role of Bcl-2 and its post-transcriptional modification in response to antitumor therapy. Biochem Pharmacol 61:381–386PubMedCrossRef

42.

van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, Willis SN, Scott CL, Day CL, Cory S, Adams JM, Roberts AW, Huang DCS (2006) The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10:389–399PubMedCrossRef

43.

Bingle CD, Craig RW, Swales BM, Singleton V, Zhou P, Whyte MKB (2000) Exon skipping in Mcl-1 results in a Bcl-2 homology domain 3 only gene product that promotes cell death. J Biol Chem 275:22136–22146PubMedCrossRef

44.

Herrant M, Jacquel A, Marchetti S, Belhacene N, Colosetti P, Luciano F, Auberger P (2004) Cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-induced apoptosis. Oncogene 23:7863–7873PubMedCrossRef

45.

Jamil S, Sobouti R, Hojabrpour P, Raj M, Kast J, Duronio V (2005) A proteolytic fragment of Mcl-1 exhibits nuclear localization and regulates cell growth by interaction with Cdk1. Biochem J 387:659–667PubMedCrossRef

46.

Marriott HM, Bingle CD, Read RC, Braley E, Kroemer G, Hellewell PG, Craig RW, Whyte MKB, Dockrell DH (2005) Dynamic changes in Mcl-1 expression regulate macrophage viability or commitment to apoptosis during bacterial clearance. J Clin Invest 115:359–368PubMedCrossRef

47.

Weng C, Li Y, Xu D, Shi Y, Tang H (2005) Specific cleavage of Mcl-1 by caspase-3 in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Jurkat leukemia T cells. J Biol Chem 280:10491–10500PubMedCrossRef

48.

Cowell LN, Graham JD, Bouton AH, Clarke CL, O’Neill GM (2006) Tamoxifen treatment promotes phosphorylation of the adhesion molecules, p130Cas/BCAR1, FAK and Src, via an adhesion-dependent pathway. Oncogene 25:7597–7607PubMedCrossRef

49.

Sharma SV, Gajowniczek P, Way IP, Lee DY, Jiang J, Yuza Y, Classon M, Haber DA, Settleman J (2006) A common signaling cascade may underlie “addiction” to the Src, BCR-ABL,and EGF receptor oncogenes. Cancer Cell 10:425–435PubMedCrossRef

50.

Recchia I, Rucci N, Funari A, Miggliaccio S, Taranta A, Longo M, Kneissel M, Susa M, Fabbro D, Teti A (2004) Reduction of c-Src activity by substituted 5,7-diphenyl-pyrrolo [2,3-d]-pyrimidines induces osteoclast apoptosis in vivo and in vitro. Involvement of ERK 1/2 pathway. Bone 34:65–79PubMedCrossRef

Title: Targeting c-Src kinase enhances tamoxifen’s inhibitory effect on cell growth by modulating expression of cell cycle and survival proteins
Authors: Maricarmen D. Planas-Silva
Kecia N. Hamilton
Publication date: 01-09-2007
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 4/2007
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-006-0398-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2007

Preclinical antitumor activity of the oral platinum analog satraplatin

A limited sampling strategy to estimate individual pharmacokinetic parameters of methotrexate in children with acute lymphoblastic leukemia

Trichosanthin down-regulated p210Bcr-Abl and enhanced imatinib-induced growth arrest in chronic myelogenous leukemia cell line K562

A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic adenocarcinoma

Plasma and cerebrospinal fluid pharmacokinetics of intravenously administered ABT-751 in non-human primates

Long-term effects of 7-monohydroxyethylrutoside (monoHER) on DOX-induced cardiotoxicity in mice

Keynote webinar | Spotlight on antibody–drug conjugates in cancer